Revealing Increased Axonal Loss in Treated HIV Patients

HIV patients may suffer sooner from aging than average population, including brain aging. Our hypothesis is that if brain dysfunctions are explained by a quicker loss of neurons in HIV patients, this loss could be detected earlier by a thinning down of retinal nerve fiber layer (RNFL), compared to non HIV patients of the same age.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

HIV Seropositivity Blood-Borne Infections Communicable Diseases Genital Diseases HIV Infections Immune System Diseases Immunologic Deficiency Syndromes Infections Lentivirus Infections RNA Virus Infections Retroviridae Infections Sexually Transmitted Diseases Sexually Transmitted Diseases, Viral Urogenital Diseases Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Fondation OPH A de Rothschild

Paris, Île-de-France Region, 75019, France

About this study

The investigators aim to compare the thickness of the RNFL and the thickness of the RCGs measured by spectral domain OCT between patients infected by HIV and patients of same age non infected by HIV.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

HIV infection known since at least 10 years
viral load undetectable under ARV treatment since at least 5 years, whatever the type of ARV
lymphocytes CD4 > 350, whatever the CD4 nadir
signed informed consent

Exclusion criteria

History of ocular pathology, eye surgery, or intraocular injection
Familial History of glaucoma
ametropia (>3 dioptres on the sphere and >1,5 dioptres on the cylinder)
known neurological pathology, active or former
History of ethambutol or synthetic antimalarial drug consumption
History of chemotherapy
Active and regular use of drugs
non-weaned chronic alcoholism
contra indication to MRI
diabetes
cognitive disorders (MoCA<26)
non covered by health insurance
patient under legal protection
pregnant or breast-feeding woman
Non inclusion criteria for control patients: known HIV infection

Treatment and study plan

ophthalmologic examination and MRI

Other

thorough investigation of patients, not included in usual care.

Primary outcomes

thickness of the RNFL and the RCGs measured by spectral domain OCT, between the two groups of patients

Time frame: one day of examinations

Sponsors and collaborators

Lead sponsor

Fondation Ophtalmologique Adolphe de Rothschild

Network

Registry information

Acronym: OCTIHIV

Important dates

Study start: 2013
Primary completion: 2015
First posted: Dec 6, 2013
Registry last updated: Oct 21, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed